COMPANY PROFILE

Orbus Therapeutics

Explore full profile

Orbus Therapeutics is dedicated to developing products that treat rare diseases

North Fair Oaks, United StatesFounded 2012Biotech & Life Sciences

Valuation $50–100M Last recorded · 2017

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Orbus Therapeutics

Orbus Therapeutics is a biopharmaceutical company dedicated to developing innovative therapies for rare diseases, particularly those for which there are few, if any, effective treatments. The company is currently focused on the development and commercialization of eflornithine, a drug aimed at treating recurrent anaplastic astrocytoma, a type of brain cancer. Orbus Therapeutics operates in the niche market of rare diseases, serving patients who are significantly underserved by existing medical treatments. The business model revolves around the research, development, and eventual commercialization of specialized drugs, with revenue generated through the sale of these therapies once they receive regulatory approval. The company is currently in the Phase 3 clinical trial stage for its lead product, eflornithine, and is actively enrolling patients. Orbus Therapeutics aims to improve the health and quality of life for patients facing life-threatening or significantly life-altering diseases.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2012
Headquarters: North Fair Oaks, United States
Employees: 1
Open positions: None listed
Dealroom signal: 24.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Oncology, Neurology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VCOther financing	Aug 2020	$10M	$40M	Undisclosed	—
SERIES BOther financing	Aug 2017	$13M	$50M	Undisclosed	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Orbus Therapeutics website traffic

Latest recorded traffic for Orbus Therapeutics is 2.9K monthly website visits, up 163.6% over the last three months. Orbus Therapeutics's team declined 50% over the past year.

Latest monthly visits2.9K 3-month web change+163.6% 1-year team growth-50%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
XPX4 PharmaceuticalsClinical-stage oncology company developing best-in-class oral small molecule CXCR4 antagonists for the treatment	Cambridge, United States	Operational	78	$172M	$226M
ANAnavexBiopharmaceutical company developing drugs for the treatment of cancer and neurological diseases	New York City, United States	Operational
ATArmaGen TechnologiesArmaGen \| Revolutionary Therapies for Severe Neurological Diseases \| ArmaGen	Calabasas, United States	Acquired
BGBlueprint GeneticsUses Next Generation Sequencing (NGS) to perform diagnostics on genetic diseases	Espoo, Finland	Operational
RPRaptor PharmaceuticalsEngages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of	Novato, United States	Acquired
CACavionClinical stage pharmaceutical company committed to providing patients with therapies	Charlottesville, United States	Acquired
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
MTMonopar TherapeuticsEmerging biopharmaceutical company focused on developing orphan oncology compounds	Lake Forest, United States	Operational